Concord Drugs Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 605306,
    "name": "Concord Drugs",
    "stock_name": "Concord Drugs",
    "full_name": "Concord Drugs Ltd",
    "name_url": "stocks-analysis/concord-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "80.85",
    "chg": 3.85,
    "chgp": "5.0%",
    "dir": 1,
    "prev_price": "77.00",
    "mcapval": "80.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 538965,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE858L01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "13.7 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/concord-drugs-605306-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Concord Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-concord-drugs-overvalued-or-undervalued-3742700",
        "imagepath": "",
        "date": "2025-12-03 08:14:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Understanding Concord Drugs’ Valuation Metrics</strong></p>\n<p>At first glance, Concord Drugs’ price-to-earnings (PE) ratio stands out at an elevated 135.16, which is significantly higher than many of its pharmaceutical peers. This figure typically implies a premium valuation, often justified by expectations of robust future earnings growth. However, the company’s price-to-book value of 2.28 and enterprise value to EBITDA (EV/EBITDA) ratio of 20.90 present a more nuanced picture. These multiples, while above average, are not excessively stretched when compared to the broader pharmaceutical sector.</p>\n<p>Moreover, the PEG ratio of 0.63 is particularly noteworthy. A PEG ratio below 1 generally indicates that the stock is undervalued relative to its earnings growth rate, suggesting that Concor..."
      },
      {
        "title": "How has been the historical performance of Concord Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-drugs-3739202",
        "imagepath": "",
        "date": "2025-12-01 23:06:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the fiscal years ending March 2022 to March 2025, Concord Drugs’ net sales have shown a downward trend, decreasing from ₹59.06 crores in March 2022 to ₹45.25 crores in March 2025. This represents a significant contraction in top-line revenue, with the most notable drop occurring between March 2022 and March 2023. The absence of other operating income throughout this period indicates that the company’s revenue streams have been solely reliant on its core sales operations.</p>\n<p>Correspondingly, the total expenditure excluding depreciation has also declined, from ₹53.37 crores in March 2022 to ₹41.11 crores in March 2025, reflecting cost adjustments in line with reduced sales. Raw material costs, a major expense component, fell from ₹44.41..."
      },
      {
        "title": "Concord Drugs Surges with Unprecedented Buying Interest, Eyes Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-hits-upper-circuit-amid-unprecedented-buying-interest-3731266",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordDrugs_only_buyers_3731266.png",
        "date": "2025-11-26 11:00:26",
        "description": "Concord Drugs has captured market attention with extraordinary buying momentum, registering a sharp price rise and entering an upper circuit scenario marked by an absence of sellers. This surge reflects robust investor enthusiasm and hints at a potential multi-day rally in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Concord Drugs Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-surges-on-unprecedented-buying-interest-hits-upper-circuit-3728940",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordDrugs_only_buyers_3728940.png",
        "date": "2025-11-25 11:45:39",
        "description": "Concord Drugs has witnessed extraordinary buying momentum today, with the stock hitting an upper circuit and a complete absence of sellers in the queue. This remarkable demand surge signals the potential for a sustained multi-day circuit scenario, reflecting strong investor confidence in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Concord Drugs Faces Intense Selling Pressure Amid Consecutive Declines",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-drugs-faces-severe-selling-pressure-amid-lower-circuit-lockdown-3724220",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordDrugs_only_sellers_3724220.png",
        "date": "2025-11-24 09:40:36",
        "description": "Concord Drugs Ltd has encountered significant selling pressure in recent sessions, with the stock registering a sharp decline over the past four days and exhibiting a complete absence of buyers today. This sustained downward momentum highlights distress selling signals within the Pharmaceuticals & Biotechnology sector, contrasting sharply with broader market trends."
      },
      {
        "title": "Why is Concord Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-concord-drugs-fallingrising-3721931",
        "imagepath": "",
        "date": "2025-11-22 00:39:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Concord Drugs has experienced a notable correction in the past week, with the stock declining by 8.77%, contrasting sharply with the Sensex’s modest gain of 0.79% over the same period. This underperformance is particularly striking given the stock’s impressive longer-term returns, including a year-to-date gain exceeding 108% and a one-year return of nearly 124%, far outpacing the Sensex’s 10.47% over the same timeframe. Over five years, Concord Drugs has surged by approximately 230%, underscoring its strong growth trajectory relative to the broader market’s 94.23% rise.</p>\n<p>Despite these robust fundamentals, the recent price action suggests a phase of profit-taking or short-term caution among investors. The stock’s current price is ..."
      },
      {
        "title": "How has been the historical performance of Concord Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-drugs-3708623",
        "imagepath": "",
        "date": "2025-11-17 22:57:55",
        "description": "Answer:\nThe historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four fiscal years.\n\nBreakdown:\nConcord Drugs reported net sales of 45.25 Cr for the year ending March 2025, a slight increase from 44.93 Cr in March 2024, but a notable decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025 compared to 44.93 Cr in the previous year, while it was significantly higher in earlier years. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, reflecting a gradual decrease from 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, which is a slight increase from 4.05 Cr in March 2024 but down from 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax also declined to 0.69 Cr in March 2025 from 1.25 Cr in March 2023 and 2.25 ..."
      },
      {
        "title": "Concord Drugs Q2 FY26: Profit Surge Masks Revenue Decline in Challenging Quarter",
        "link": "https://www.marketsmojo.com/news/result-analysis/concord-drugs-q2-fy26-profit-surge-masks-revenue-decline-in-challenging-quarter-3716609",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordDrugs_quaterlyResult_3716609.png",
        "date": "2025-11-15 10:03:54",
        "description": "Concord Drugs Limited, a Hyderabad-based pharmaceutical manufacturer specialising in injectables and finished formulations, reported a net profit of ₹0.19 crores for Q2 FY26, marking a substantial 375.00% increase year-on-year from ₹0.04 crores in Q2 FY25. However, the profitability improvement came against a backdrop of declining revenues, with net sales falling 16.90% YoY to ₹10.28 crores. The company's stock, trading at ₹89.70 with a micro-cap market capitalisation of ₹82.00 crores, has surged 150.21% over the past year despite weak fundamental metrics including an anaemic ROE of 1.83% and elevated P/E ratio of 155x."
      },
      {
        "title": "How has been the historical performance of Concord Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-drugs-3703038",
        "imagepath": "",
        "date": "2025-11-14 23:43:42",
        "description": "Answer:\nThe historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years.\n\nBreakdown:\nConcord Drugs reported net sales of 45.25 Cr in March 2025, a slight increase from 44.93 Cr in March 2024, but a notable decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, compared to 44.93 Cr in the previous year, but down from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, which was slightly higher than 40.88 Cr in March 2024, but lower than 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, showing a marginal increase from 4.05 Cr in March 2024, but down from 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax also declined to 0.69..."
      }
    ],
    "total": 256,
    "sid": "605306",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/concord-drugs-605306"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Quarterly Results",
      "datetime": "02-Feb-2026",
      "details": "Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Un-Audited financials Results for Quarter ending Dec 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "20-Jan-2026",
      "details": "Certificate under Reg 74(5) of SEBI (DP) regulations",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
      "datetime": "30-Dec-2025",
      "details": "Company has received purchase orders from various entities for supply of its products.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Concord Drugs overvalued or undervalued?

2025-12-03 08:14:03

Understanding Concord Drugs’ Valuation Metrics At first glance, Concord Drugs’ price-to-earnings (PE) ratio stands out at an elevated 135.16, which is significantly higher than many of its pharmaceutical peers. This figure typically implies a premium valuation, often justified by expectations of robust future earnings growth. However, the company’s price-to-book value of 2.28 and enterprise value to EBITDA (EV/EBITDA) ratio of 20.90 present a more nuanced picture. These multiples, while above average, are not excessively stretched when compared to the broader pharmaceutical sector. Moreover, the PEG ratio of 0.63 is particularly noteworthy. A PEG ratio below 1 generally indicates that the stock is undervalued relative to its earnings growth rate, suggesting that Concor...

How has been the historical performance of Concord Drugs?

2025-12-01 23:06:05

Revenue and Profitability Trends Over the fiscal years ending March 2022 to March 2025, Concord Drugs’ net sales have shown a downward trend, decreasing from ₹59.06 crores in March 2022 to ₹45.25 crores in March 2025. This represents a significant contraction in top-line revenue, with the most notable drop occurring between March 2022 and March 2023. The absence of other operating income throughout this period indicates that the company’s revenue streams have been solely reliant on its core sales operations. Correspondingly, the total expenditure excluding depreciation has also declined, from ₹53.37 crores in March 2022 to ₹41.11 crores in March 2025, reflecting cost adjustments in line with reduced sales. Raw material costs, a major expense component, fell from ₹44.41...

Concord Drugs Surges with Unprecedented Buying Interest, Eyes Multi-Day Upper Circuit

2025-11-26 11:00:26

Concord Drugs has captured market attention with extraordinary buying momentum, registering a sharp price rise and entering an upper circuit scenario marked by an absence of sellers. This surge reflects robust investor enthusiasm and hints at a potential multi-day rally in the Pharmaceuticals & Biotechnology sector.

Concord Drugs Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit

2025-11-25 11:45:39

Concord Drugs has witnessed extraordinary buying momentum today, with the stock hitting an upper circuit and a complete absence of sellers in the queue. This remarkable demand surge signals the potential for a sustained multi-day circuit scenario, reflecting strong investor confidence in the Pharmaceuticals & Biotechnology sector.

Concord Drugs Faces Intense Selling Pressure Amid Consecutive Declines

2025-11-24 09:40:36

Concord Drugs Ltd has encountered significant selling pressure in recent sessions, with the stock registering a sharp decline over the past four days and exhibiting a complete absence of buyers today. This sustained downward momentum highlights distress selling signals within the Pharmaceuticals & Biotechnology sector, contrasting sharply with broader market trends.

Why is Concord Drugs falling/rising?

2025-11-22 00:39:58

Recent Price Movement and Market Context Concord Drugs has experienced a notable correction in the past week, with the stock declining by 8.77%, contrasting sharply with the Sensex’s modest gain of 0.79% over the same period. This underperformance is particularly striking given the stock’s impressive longer-term returns, including a year-to-date gain exceeding 108% and a one-year return of nearly 124%, far outpacing the Sensex’s 10.47% over the same timeframe. Over five years, Concord Drugs has surged by approximately 230%, underscoring its strong growth trajectory relative to the broader market’s 94.23% rise. Despite these robust fundamentals, the recent price action suggests a phase of profit-taking or short-term caution among investors. The stock’s current price is ...

How has been the historical performance of Concord Drugs?

2025-11-17 22:57:55

Answer: The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four fiscal years. Breakdown: Concord Drugs reported net sales of 45.25 Cr for the year ending March 2025, a slight increase from 44.93 Cr in March 2024, but a notable decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025 compared to 44.93 Cr in the previous year, while it was significantly higher in earlier years. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, reflecting a gradual decrease from 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, which is a slight increase from 4.05 Cr in March 2024 but down from 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax also declined to 0.69 Cr in March 2025 from 1.25 Cr in March 2023 and 2.25 ...

Concord Drugs Q2 FY26: Profit Surge Masks Revenue Decline in Challenging Quarter

2025-11-15 10:03:54

Concord Drugs Limited, a Hyderabad-based pharmaceutical manufacturer specialising in injectables and finished formulations, reported a net profit of ₹0.19 crores for Q2 FY26, marking a substantial 375.00% increase year-on-year from ₹0.04 crores in Q2 FY25. However, the profitability improvement came against a backdrop of declining revenues, with net sales falling 16.90% YoY to ₹10.28 crores. The company's stock, trading at ₹89.70 with a micro-cap market capitalisation of ₹82.00 crores, has surged 150.21% over the past year despite weak fundamental metrics including an anaemic ROE of 1.83% and elevated P/E ratio of 155x.

How has been the historical performance of Concord Drugs?

2025-11-14 23:43:42

Answer: The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years. Breakdown: Concord Drugs reported net sales of 45.25 Cr in March 2025, a slight increase from 44.93 Cr in March 2024, but a notable decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, compared to 44.93 Cr in the previous year, but down from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, which was slightly higher than 40.88 Cr in March 2024, but lower than 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, showing a marginal increase from 4.05 Cr in March 2024, but down from 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax also declined to 0.69...

View All News